Blank check company merger creates cancer specialist Vincera

LifeSci Acquisition – a so-called ‘blank check’ company – has announced a $60 million merger with Vincera Pharma that will focus on developing cancer drugs.

The combined company will be called Vincera and will focus its initial energies on a clinical-stage PTEFb/CDK9 inhibitor and preclinical bioconjugation platform, both licensed from German group Bayer.